As cancer continues to affect lives around the world. Biotechnology companies are more determined than ever to introduce new therapies to the market. Led by Riccardo Braglia, Swiss pharmaceutical company Helsinn Holdings is no different and continues their dedication to finding new quality cancer and rare disease care products.
Lin 2020, the company announced that they received approval in the United States from the Food and Drug Administration for their ready to dilute formulation of Akynzeo. The benefits of this drug including the following:
• The injection does not require refrigeration at any point in distribution or storage.
• It reduces the preparation process for intravenous administration by eliminating the need for reconstitution before dilution.
• Akynzeo can also be stored at room temperature for up to 24 hours.
Akynzeo was approved in capsule form in 2014 and is intended to prevent acute and delayed nausea and vomiting associated with emetogenic cancer chemotherapy in adults treated with dexamethasone. It’s also the first and only 5-HTx and NK1 receptor combination approved for treatment in chemotherapy induced nausea and vomiting. The most common adverse reactions form Akynzeo include headache, fatigue, asthenia, dyspepsia, and constipation.
Adds Helsinn CEO Riccardo Braglia. “We are pleased to announce the FDA’s approval of the liquid formulation of Akynzeo. This new formulation will reduce the steps in administering this CINV treatment, improving the efficiency in preparation. Extended storage time following dilution provides more flexibility to clinics and hospitals to prepare Akynzeo for use throughout the day. Akynzeo is the only medication to target two distinct CINV pathways in a single dose and can help clinicians prevent CINV in appropriate patients. We are targeting launch of the liquid formulation in the second half of this year and look forward to updating the market in due course.”
